Ranbaxy announces reconstitution of Board of Director
Ranbaxy Laboratories and Japanese drug major Daiichi Sankyo today jointly announced the reconstitution of the Gurgaon-based company's Board of Directors.
By PTI |
NEW DELHI: Ranbaxy Laboratories and Japanese drug major Daiichi Sankyo today jointly announced the reconstitution of the Gurgaon-based company's Board of Directors.
Ranbaxy CEO and MD Malvinder Mohan Singh will additionally assume the charge of Chairman of the Board of Directors, while Daiichi Sankyo President and CEO Takashi Shoda has also been appointed as director in the board of Ranbaxy, the Gurgaon-based company said in a release.
It has also appointed Ranbaxy Laboratories Chief Operating Officer Atul Sobti as COO in company's board.
The other members in the board are Daiichi Sankyo Senior Executive Officer Tstomu Une, Religare Enterprise Ltd CEO Sunil Godhwani, BOWS Pharmaceuticals AG General Partner Anthony H Wild, Mukand Ltd Co-Chairman and MD Rajesh V Shah, GCA Savvian Group Representative Director Akihiro Watanbe and Advocate Balinder Singh Dhillon.
The reconstitution was approved by Ranbaxy's Board of Director at a meeting held today, the company said.
Earlier in June, Daiichi has entered into an share purchase agreement with Ranbaxy for acquiring a majority stake in the company. Post acquisition, the Japanese firm acquired 63.92 per cent stake in Ranbaxy.
Ranbaxy CEO and MD Malvinder Mohan Singh will additionally assume the charge of Chairman of the Board of Directors, while Daiichi Sankyo President and CEO Takashi Shoda has also been appointed as director in the board of Ranbaxy, the Gurgaon-based company said in a release.
It has also appointed Ranbaxy Laboratories Chief Operating Officer Atul Sobti as COO in company's board.
The other members in the board are Daiichi Sankyo Senior Executive Officer Tstomu Une, Religare Enterprise Ltd CEO Sunil Godhwani, BOWS Pharmaceuticals AG General Partner Anthony H Wild, Mukand Ltd Co-Chairman and MD Rajesh V Shah, GCA Savvian Group Representative Director Akihiro Watanbe and Advocate Balinder Singh Dhillon.
The reconstitution was approved by Ranbaxy's Board of Director at a meeting held today, the company said.
Earlier in June, Daiichi has entered into an share purchase agreement with Ranbaxy for acquiring a majority stake in the company. Post acquisition, the Japanese firm acquired 63.92 per cent stake in Ranbaxy.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
